(Yicai) Nov. 25 -- Chinese drug developer Hua Medicine is terminating its agreement with German pharma giant Bayer for the distribution of its type 2 diabetes drug in China, just one year after the ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

Epigenic, Immunocan have officially moved into Bayer Co.Lab, and AccurEdit Therapeutics will join early next month. Photo: ...

Bayer is also seeing some success with newer drugs such as cancer medicine Nubeqa. It needs these to offset rising generic competition for its best-selling anti-clotting medication Xarelto ...

Bayer now says it expects to make €3 billion ... results of the phase 3 ARASENS trial in the New England Journal of Medicine. The study showed that adding Nubeqa to standard therapy with anti ...

According to The Wall Street Journal, Bayer started putting in the cotton ... More from Science We've all been there: reaching for the medicine cabinet with a splitting headache, opening the ...